论文部分内容阅读
目的:利用无创超声心动图评价不伴有心力衰竭的扩张型心肌病(DCM)患者应用美托洛尔治疗的结果。方法:入选不伴有心力衰竭的DCM患者35例,正常对照组30例。DCM患者在常规药物治疗基础上,加用美托洛尔至目标剂量或最大耐受剂量,治疗前后行常规超声心动图检测。结果:①治疗前,DCM组较正常对照组左房内径,左室舒张末期内径明显增加,左室射血分数(LVEF)降低(p<0.05);治疗1个月后各项指标与治疗前差异无统计学意义,而6个月后左房内径,左室舒张末期内径和LVEF有所改善,但与正常对照组相比仍有差异。结果:不伴有心力衰竭的DCM患者,经美托洛尔治疗1月后各项指标无明显改善,6个月后各项指标均有效改善。美托洛尔可以延缓DCM心肌病变的发展。
PURPOSE: To evaluate the results of metoprolol treatment in non-invasive echocardiography in patients with dilated cardiomyopathy (DCM) without heart failure. Methods: 35 patients with DCM without heart failure and 30 normal controls were enrolled. DCM patients on the basis of conventional drug therapy, plus metoprolol to the target dose or maximum tolerated dose, before and after treatment routine echocardiography. Results: ① Before treatment, left atrium diameter and left ventricular end-diastolic diameter in DCM group were significantly increased and left ventricular ejection fraction (LVEF) was lower than that in normal control group (p <0.05). After treatment for 1 month, The difference was not statistically significant. However, left atrial diameter, left ventricular end-diastolic diameter and LVEF improved after 6 months, but there were still differences compared with the normal control group. Results: Patients with DCM without heart failure had no significant improvement after 1 month of metoprolol treatment, and all the indicators were effectively improved after 6 months. Metoprolol can delay the development of DCM cardiomyopathy.